PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Doxribtimine→

Doxribtimine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
50-89-5
Molecular formula
C10H14N2O5
Molecular weight
242.23 g/mol
Drug class
Deoxythymidine nucleosidepyrimidine nucleoside replacement component of KYGEVVI
Mechanism of action
Supplies deoxythymidine for mitochondrial DNA nucleotide pools. In thymidine kinase 2 deficiency, the combination of deoxycytidine and deoxythymidine is intended to support mitochondrial DNA maintenance and synthesis; the individual nucleosides are administered as a fixed combination, not as separately indicated monotherapies.
Indications / reported uses
  • Component of the fixed combination doxecitine/doxribtimine (KYGEVVI) for treatment of thymidine kinase 2 deficiency (TK2d) in adults and paediatric patients with symptom onset on or before 12 years of age; not a stand-alone approved indication

Sources: US FDA — KYGEVVI (doxecitine and doxribtimine) approval listing · US DailyMed — KYGEVVI · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Doxribtimine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Doxribtimine Permitted Daily Exposure (PDE) report (the Doxribtimine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Doxribtimine Occupational Exposure Limit (OEL) report (the Doxribtimine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.